Literature DB >> 15888964

Assessment of acute phase proteins in acute ischemic stroke.

Yusuf Tamam1, Kenan Iltumur, Ismail Apak.   

Abstract

Acute phase proteins (APPs) have been implicated to play important roles during both acute and chronic inflammatory processes in different diseases including ischemic stroke. Though there are several studies showing the importance of APPs as inflammation markers in acute ischemic stroke (AIS), the time course of these proteins during acute phase of AIS is not well known. Thus, the aim of this study was to show the changes in plasma levels of six APPs (i.e., haptoglobin [Hp], ceruloplasmin [Cp], high-sensitive C-reactive protein [h-CRP], fibrinogen, complement 3 [C3] and complement 4 [C4]) during the first 10 days after acute stroke. The study group consisted of 34 female and 19 male patients (n = 53; mean age 65 +/- 12 years), who had first acute ischemic stroke (AIS). An age-matched control group (n = 53; 32 female and 21 male subjects, mean age 62 +/- 6 years) was also included. To evaluate the plasma levels of six APPs, the blood samples of patients with AIS were withdrawn on admission (day 1), and after 3, 5 and 10 days, whereas only one measurement was performed in the control group. In addition, several cerebrovascular risk factors were determined. The peak levels of APPs were higher in the AIS group than the control group (p < 0.0001). In serial measurements, the levels of h-CRP, Hp, C3 and C4 showed alterations during 10 days after AIS (p < 0.0001, p < 0.05, p < 0.0001, p < 0.0001, respectively). The alterations in levels of fibrinogen and Cp were not statistically significant (p > 0.05). After stroke, h-CRP, C3 and fibrinogen reached their highest values on the third day, Cp and C4 on the fifth day, and Hp on the tenth day. The plasma levels of h-CRP correlated positively with other five APPs studied (p < 0.05). These findings support the importance of inflammation processes after stroke. We suggest that the differences in levels of APPs could be used in predicting the outcome of stroke patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888964     DOI: 10.1620/tjem.206.91

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

Review 1.  Circulating Biomarkers in Long-Term Stroke Prognosis: A Scoping Review Focusing on the South African Setting.

Authors:  Juan Jansen van Vuuren; Somasundram Pillay; Ansuya Naidoo
Journal:  Cureus       Date:  2022-04-09

2.  Hyperfibrinogenemia and functional outcome from acute ischemic stroke.

Authors:  Gregory J del Zoppo; David E Levy; Warren W Wasiewski; Arthur M Pancioli; Andrew M Demchuk; James Trammel; Bart M Demaerschalk; Markku Kaste; Gregory W Albers; Eric B Ringelstein
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

3.  Dynamics of inflammatory factors expression in ischemic brain tissue injury.

Authors:  Tonko Marinović; Silvio Bašić; Dominik Romić; Branimir Nevajda; Lovorka Đerek; Jurica Maraković; Marina Raguž
Journal:  Neurol Int       Date:  2019-12-02

4.  Cardioembolic and small vessel disease stroke show differences in associations between systemic C3 levels and outcome.

Authors:  Anna Stokowska; Sandra Olsson; Lukas Holmegaard; Katarina Jood; Christian Blomstrand; Christina Jern; Marcela Pekna
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

5.  The sustained increase of plasma fibrinogen during ischemic stroke predicts worse outcome independently of baseline fibrinogen level.

Authors:  Marta Swarowska; Aleksandra Janowska; Agnieszka Polczak; Aleksandra Klimkowicz-Mrowiec; Joanna Pera; Agnieszka Slowik; Tomasz Dziedzic
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.